MediWound Ltd (id:6811 MDWD)
17.89 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/25/2024 11:02:02 AM)
Exchange open, closes in 4 hours 57 minutes
About MediWound Ltd
Market Capitalization 180.84M
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
| Headquarters (address) |
42 Hayarkon Street Yavne 8122745 Israel |
| Phone | 972 7 797 14100 |
| Website | https://www.mediwound.com |
| Employees | 100 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | MDWD |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 10.14 - 24.00 |
| Market Capitalization | 180.84M |
| P/E trailing | -23.85 |
| P/E forward | -7.55 |
| Price/Sale | 8.98 |
| Price/Book | 4.89 |
| Beta | 3.00 |
| EPS | -2.91 |
| EPS Israel (ID:92, base:52) | 3.00 |